Aspirin prices in the United States recorded a remarkable decline in March, which worked against the growing trend observed in the previous month. According to market sources, this reduction was associated with a high level of inventory and insufficient aspirin demand from the subsequent formulation industry. The market continued to be supersaturated because the buyers delivered considerable orders earlier, which reduced the need for further purchases.

In addition, increased competition among local suppliers has deteriorated downward pressure because they focused on maintaining their market share in the face of excess. Buyers, alert before the possibility of continuing price drop, postponed their purchases and expected a further reduction in the short term.

A significant decline in aspirin prices in the United States during March can be attributed to the shifting international trade dynamics, especially concerning China and India, which are the main exporters of active pharmaceutical components (API). As these nations give a substantial part of global active pharmaceutical components, including aspirin, any changes in business policies or tariffs directly affect the pharmaceutical market in the United States.

The international trade tensions escalated to new heights on March 4th after U.S. President Donald Trump enacted 25% duties for Mexican and Canadian goods and Chinese products. The announcements induced concerns regarding pharmaceutical supply chain stability while U.S. buyers reduced purchases through expecting changes in policies and market fluctuations. As a result, USA market experienced an immediate decrease in aspirin demand due to these developments.

The planned imposition of US tariffs on Indian pharmaceuticals in early April has exacerbated existing pressures on the industry. With the United States receiving over 30% of India's pharmaceutical exports, the sector is facing substantial strain, potentially driving up production and export costs, particularly for companies already operating on thin margins. In advance of the tariffs, a likely surge in Indian exports to the US in March created a temporary oversupply in the American market. This glut, combined with subdued demand, has triggered a significant drop in aspirin prices.

Concerns over putting into effect new reciprocal tariffs and non-tariff barriers on India and other foreign exporters further increased market uncertainty. As a result, US buyers and distributors started being cautious, then defer new purchases and running down of existing stock to minimize the risk and keep aspirin prices down. Together with pre-emptive stockpiling and unstable demand, these elements contributed towards a fall in aspirin prices over the course of the month.

As per the ChemAnalyst report the prices of aspirin in the United States will probably increase throughout upcoming months. Multiple factors contribute to this anticipated price increase including the end of surplus in March and mounting trade expenses along with American import duties on Indian drugs which started in April. This situation could lead to reduced supplies available in the market. The continuation of regular purchasing and depletion of existing inventories by distributors will create rising demand for aspirin while pushing prices higher.